Main adverse events | No. of studies | Immunosuppressive agent group | Control group | RR (95% CI) | P value | ||
---|---|---|---|---|---|---|---|
FE | RE | FE | RE | ||||
Gastrointestinal | 11 | 38/431 | 8/606 | 2.53 [1.15, 5.55] | 2.42[1.07, 5.45] | 0.02 | 0.03 |
Hematologic | 9 | 16/373 | 6/551 | 2.17 [1.00, 4.68] | 2.0[0.84, 4.77] | 0.05 | 0.12 |
Dermatologic | 7 | 16/273 | 3/463 | 4.09 [1.57, 10.66] | 3.88[1.41, 10.64] | 0.004 | 0.009 |
Hepatotoxicity | 7 | 21/455 | 19/636 | 1.26 [0.72, 2.22] | 1.26[0.70, 2.24] | 0.42 | 0.44 |
Respiratory | 6 | 9/371 | 12/544 | 0.81 [0.37, 1.74] | 0.82[0.37, 1.82] | 0.58 | 0.62 |
Infection | 6 | 189/373 | 114/547 | Not estimable | Not estimable | Not estimable | Not estimable |
Impaired glucose tolerance or diabetes mellitus | 5 | 15/326 | 5/316 | 2.61 [1.04, 6.55] | 2.16[0.77, 6.05] | 0.04 | 0.14 |
Elevation of blood pressure | 4 | 14/193 | 16/389 | 0.96 [0.52, 1.79] | 0.97[0.43, 2.22] | 0.9 | 0.95 |
Malignant | 4 | 4/167 | 2/157 | 1.40 [0.39, 4.98] | 1.33[0.30, 5.93] | 0.61 | 0.71 |
Musculoskeletal | 3 | 5/238 | 3/226 | 1.47 [0.44, 4.93] | 1.37[0.40, 4.71] | 0.53 | 0.62 |
Hyperkalemia | 3 | 2/156 | 11/350 | 0.23 [0.07, 0.71] | 0.3[0.05, 1.98] | 0.01 | 0.21 |
Genitourinary | 3 | 6/59 | 0/56 | 4.59 [0.85, 24.85] | 4.07[0.71, 23.39] | 0.08 | 0.12 |
Death | 2 | 3/218 | 2/206 | 1.42 [0.24, 8.44] | 1.41 [0.23, 8.55] | 0.70 | 0.71 |